| Literature DB >> 35932031 |
Tsuneyuki Uchida1, Ryuichi Sekine2, Kenichi Matsuo2, Gaku Kigawa2, Takahiro Umemoto2, Mikio Makuuchi2,3, Kuniya Tanaka2.
Abstract
BACKGROUND: Day of the week when elective gastrointestinal surgery is performed may be influenced by various background and tumor-related factors. Relationships between postoperative outcome and when in the week gastrectomy is performed remain controversial. We undertook this study to evaluate whether weekday of gastrectomy influenced outcomes of gastric cancer treatment ("weekday effect").Entities:
Keywords: Gastrectomy; Gastric cancer; Prognosis; Propensity score matching; Weekday effect
Mesh:
Year: 2022 PMID: 35932031 PMCID: PMC9356429 DOI: 10.1186/s12893-022-01756-z
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1Flow chart of study including patient selection and group assignment
Comparison of early and late weekday groups (EW and LW) before and after propensity score matching
| All patients (n = 554) | Propensity score-matched patients (n = 432) | |||||
|---|---|---|---|---|---|---|
| EW group (n = 239) | LW group (n = 315) | EW group (n = 216) | LW group (n = 216) | |||
| Age, years (median, IQR) | 70 (62–77) | 70 (63–77) | 0.717 | 70 (62–77) | 69 (62–77) | 0.889 |
| Gender (n, %) | 0.521 | 0.760 | ||||
| Male | 159 (66.5%) | 218 (69.2%) | 145 (67.1%) | 141 (65.3%) | ||
| Female | 80 (33.5%) | 97 (30.8%) | 71 (32.9%) | 75 (34.7%) | ||
| Time period (n, %) | 0.103 | 0.101 | ||||
| 2004–2010 | 104 (43.5%) | 160 (50.8%) | 91 (42.1%) | 109 (50.5%) | ||
| 2011–2017 | 135 (56.5%) | 155 (49.2%) | 125 (57.9%) | 107 (49.5%) | ||
| BMI, kg/m2 (median, IQR) | 22.7 (20.9–24.5) | 22.5 (20.3–24.4) | 0.161 | 22.8 (20.9–24.5) | 22.7 (20.7–24.9) | 0.806 |
| Diabetes mellitus (n, %) | 1.000 | |||||
| Absent | 202 (84.5%) | 267 (84.8%) | 182 (84.3%) | 182 (84.3%) | 1.000 | |
| Present | 37 (15.5%) | 48 (15.2%) | 34 (15.7%) | 34 (15.7%) | ||
| COPD (n, %) | 0.719 | 1.000 | ||||
| Absent | 226 (94.6%) | 295 (93.7%) | 203 (94.0%) | 202 (93.5%) | ||
| Present | 13 (5.4%) | 20 (6.3%) | 13 (6.0%) | 14 (6.5%) | ||
| Hemoglobin, g/dl (median, IQR) | 12.7 (11.7–13.9) | 12.7 (11.1–13.7) | 0.167 | 12.7 (11.7–13.9) | 12.8 (11.6–13.9) | 0.803 |
| Albumin, g/dl (median, IQR) | 4.1 (3.9–4.4) | 4.0 (3.7–4.3) | 0.021 | 4.1 (3.9–4.4) | 4.1 (3.8–4.4) | 0.750 |
| CEA, ng/ml (median, IQR) | 1.6 (0.9–2.6) | 1.6 (1.0–2.5) | 0.834 | 1.6 (0.9–2.6) | 1.6 (0.9–2.5) | 0.983 |
| CA19-9, U/ml (median, IQR) | 9.4 (6.0–15.6) | 10 (6.8–17.3) | 0.161 | 9.6 (6.4–15.8) | 10 (6.5–17.0) | 0.371 |
| Impairment of respiratory function (n, %) | 0.271 | 1.000 | ||||
| Absent | 156 (65.3%) | 220 (69.8%) | 141 (65.3%) | 140 (64.8%) | ||
| Present | 83 (34.7%) | 95 (30.2%) | 75 (34.7%) | 76 (35.2%) | ||
| Clinical tumor depth (n, %) | 0.399 | 0.881 | ||||
| cT1 | 127 (53.1) | 154 (48.9) | 116 (53.7%) | 121 (56.0%) | ||
| cT2 | 54 (22.6) | 65 (20.6) | 49 (22.7%) | 47 (21.8%) | ||
| cT3 | 35 (14.6) | 53 (16.8) | 34 (15.7%) | 29 (13.4%) | ||
| cT4 | 23 (9.6) | 43 (13.7) | 17 (7.9%) | 19 (8.8%) | ||
| Clinical lymph node metastasis (n, %) | 0.056 | 0.545 | ||||
| cN0 | 187 (78.2%) | 215 (68.3%) | 172 (80.0%) | 160 (74.1%) | ||
| cN1 | 40 (16.7%) | 72 (22.9%) | 34 (15.7%) | 44 (20.4%) | ||
| cN2 | 11 (4.6%) | 25 (7.9%) | 9 (4.2%) | 10 (4.6%) | ||
| cN3 | 1 (0.4%) | 3 (1.0%) | 1 (0.5%) | 2 (0.9%) | ||
| Clinical TNM stage (n, %) | 0.075 | 0.180 | ||||
| I | 165 (69.0%) | 193 (61.3%) | 150 (69.4%) | 149 (69.0%) | ||
| IIA | 16 (6.7%) | 26 (8.3%) | 15 (6.9%) | 19 (8.8%) | ||
| IIB | 22 (9.2%) | 22 (7.0%) | 22 (10.2%) | 11 (5.1%) | ||
| III | 36 (15.1%) | 73 (23.2%) | 29 (13.4%) | 36 (16.7%) | ||
| IVA | 0 | 1 (0.3%) | 0 | 1 (0.5%) | ||
| Operative procedure (n, %) | 0.448 | 0.915 | ||||
| Distal gastrectomy | 168 (70.3%) | 222 (70.5%) | 155 (71.8%) | 153 (70.8%) | ||
| Proximal gastrectomy | 3 (1.3%) | 1 (0.3%) | 0 | 0 | ||
| Total gastrectomy | 68 (28.4%) | 92 (29.2%) | 61 (28.2%) | 63 (29.2%) | ||
| Operative approach (n, %) | 0.059 | 0.176 | ||||
| Open | 107 (44.8%) | 167 (53.0%) | 91 (42.1%) | 106 (49.1%) | ||
| Laparoscopic | 132 (55.2%) | 148 (47.0%) | 125 (57.9%) | 110 (50.9%) | ||
| Lymph node dissection (n, %) | 0.230 | 1.000 | ||||
| D1/D1+ | 127 (53.1%) | 150 (47.6%) | 117 (54.2%) | 116 (53.7%) | ||
| D2 or more | 112 (46.9%) | 165 (52.4%) | 99 (45.8%) | 100 (46.3%) | ||
BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen
Comparison of postoperative outcomes and pathologic findings between early and late weekday groups (EW and LW)
| All patients (n = 554) | Propensity score-matched patients (n = 432) | |||||
|---|---|---|---|---|---|---|
| EW group (n = 239) | LW group (n = 315) | EW group (n = 216) | LW group (n = 216) | |||
| Operative time, minutes (median, IQR) | 350 (290–421) | 345 (277–420) | 0.530 | 350 (290–420) | 341 (280–420) | 0.703 |
| Operative blood loss, grams (median, IQR) | 202 (39–482) | 265 (45–645) | 0.095 | 195 (30–460) | 230 (40–639) | 0.182 |
| Blood transfusion (n, %) | 0.581 | 0.499 | ||||
| Not performed | 198 (82.9%) | 255 (80.9%) | 181 (83.8%) | 187 (86.6%) | ||
| Performed | 41 (17.1%) | 60 (19.1%) | 35 (16.2%) | 29 (13.5%) | ||
| Hospital stay after surgery, days (median, IQR) | 13 (11–17) | 13 (11–18) | 0.47 | 13 (10–17) | 13 (10–18) | 0.907 |
| Death within 30 days after surgery (n, %) | 0 | 2 (0.6%) | 0.508 | 0 | 2 (0.9%) | 0.499 |
| In-hospital death (n, %) | 0 | 4 (1.3%) | 0.137 | 0 | 2 (0.9%) | 0.499 |
| Adjuvant chemotherapy (n, %) | 0.211 | 0.788 | ||||
| Absent | 204 (85.4%) | 255 (81.0%) | 182 (84.3%) | 185 (85.7%) | ||
| Present | 35 (14.6%) | 60 (19.0%) | 34 (15.7%) | 31 (14.3%) | ||
| Tumor diameter, mm (median, IQR) | 35 (25–50) | 35 (22–60) | 0.318 | 35 (25–50) | 34 (20–50) | 0.531 |
| Retrieved number of lymph nodes (median, IQR) | 40 (27–50) | 38 (26–53) | 0.922 | 39 (27–49) | 38 (25–53) | 0.930 |
| Pathological tumor depth (n, %) | 0.049 | 0.660 | ||||
| pT1 | 134 (56.1%) | 150 (47.6%) | 123 (56.9%) | 119 (55.1%) | ||
| pT2 | 41 (17.1%) | 53 (16.8%) | 39 (18.1%) | 40 (18.5%) | ||
| pT3 | 43 (18.0%) | 61 (19.4%) | 39 (18.1%) | 35 (16.2%) | ||
| pT4 | 21 (8.8%) | 51 (16.2%) | 15 (6.9%) | 22 (10.2%) | ||
| Pathological lymph node metastasis (n, %) | 0.018 | 0.844 | ||||
| pN0 | 173 (72.4%) | 204 (64.8%) | 156 (72.2%) | 161 (74.5%) | ||
| pN1 | 29 (12.1%) | 49 (15.6%) | 29 (13.4%) | 24 (11.1%) | ||
| pN2 | 10 (4.2%) | 33 (10.5%) | 10 (4.6%) | 12 (5.6%) | ||
| pN3 | 27 (11.3%) | 29 (9.2%) | 21 (9.7%) | 19 (8.8%) | ||
| Pathological TNM stage (n, %) | 0.075 | 0.992 | ||||
| IA | 120 (50.2%) | 136 (43.2%) | 109 (50.5%) | 109 (50.5%) | ||
| IB | 42 (17.6%) | 47 (14.9%) | 40 (18.5%) | 41 (19.0%) | ||
| IIA | 24 (10.0%) | 35 (11.1%) | 23 (10.7%) | 24 (11.1%) | ||
| IIB | 19 (8.0%) | 33 (10.5%) | 16 (7.4%) | 12 (5.6%) | ||
| IIIA | 8 (3.4%) | 37 (11.8%) | 8 (3.7%) | 10 (4.6%) | ||
| IIIB | 20 (8.4%) | 17 (5.4%) | 15 (6.9%) | 15 (6.9%) | ||
| IIIC | 6 (2.5%) | 10 (3.2%) | 5 (2.3%) | 5 (2.3%) | ||
IQR interquartile range
Comparison of postoperative complications between early and late weekday groups (EW and LW)
| All patients (n = 554) | Propensity score-matched patients (n = 432) | |||||
|---|---|---|---|---|---|---|
| EW group (n = 239) | LW group (n = 315) | EW group (n = 216) | LW group (n = 216) | |||
| All postoperative complications (n, %) | 49 (20.5%) | 87 (27.6%) | 0.059 | 44 (20.4%) | 52 (24.1%) | 0.418 |
| Anastomotic leakage | 6 (2.5%) | 10 (3.2%) | 0.800 | 6 (2.8%) | 7 (3.2%) | 1.000 |
| Pancreatic fistula | 8 (3.4%) | 10 (3.2%) | 1.000 | 6 (2.8%) | 7 (3.2%) | 1.000 |
| Intra-abdominal abscess | 6 (2.5%) | 14 (4.4%) | 0.258 | 5 (2.3%) | 9 (4.2%) | 0.416 |
| Anastomotic stenosis | 3 (1.3%) | 5 (1.6%) | 1.000 | 3 (1.4%) | 4 (1.9%) | 1.000 |
| Pneumonia | 5 (2.1%) | 23 (7.3%) | 0.006 | 5 (2.3%) | 12 (5.6%) | 0.136 |
| Paralytic ileus | 5 (2.1%) | 2 (0.6%) | 0.147 | 5 (2.3%) | 1 (0.5%) | 0.216 |
| Stasis syndrome | 6 (2.5%) | 4 (1.3%) | 0.341 | 5 (2.3%) | 2 (0.9%) | 0.449 |
| Surgical site infection | 2 (0.8%) | 3 (1.0%) | 1.000 | 2 (0.9%) | 3 (1.4%) | 1.000 |
| Urinary-tract infection | 2 (0.8%) | 3 (1.0%) | 1.000 | 2 (0.9%) | 3 (1.4%) | 1.000 |
| Bacteremia | 2 (0.8%) | 8 (2.5%) | 0.200 | 2 (0.9%) | 5 (2.3%) | 0.449 |
| Delirium | 6 (2.5%) | 10 (3.2%) | 0.800 | 6 (2.8%) | 5 (2.3%) | 1.000 |
| Pleural effusion | 2 (0.8%) | 2 (0.6%) | 1.000 | 2 (0.9%) | 1 (0.5%) | 1.000 |
| Heart failure | 4 (1.7%) | 8 (2.5%) | 0.567 | 3 (1.4%) | 4 (1.9%) | 1.000 |
| Bleeding | 2 (0.8%) | 0 | 0.186 | 2 (0.9%) | 0 | 0.499 |
| Enteritis | 1 (0.4%) | 3 (1.0%) | 0.638 | 1 (0.5%) | 1 (0.5%) | 1.000 |
| Other | 3 (1.3%) | 7 (2.2%) | 0.527 | 3 (1.4%) | 3 (1.4%) | 1.000 |
Fig. 2Kaplan–Meier curves comparing EW and LW for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients
Fig. 3Kaplan–Meier curves comparing EW and LW for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients
Comparison of Monday and Friday groups before and after propensity score matching
| Patients undergoing surgery on Mon. and Fri. (n = 437) | Propensity score-matched patients (n = 334) | |||||||
|---|---|---|---|---|---|---|---|---|
| Mon. group (n = 233) | Fri. group (n = 204) | Mon. group (n = 167) | Fri. group (n = 167) | |||||
| Age, years (median, IQR) | 70 (62–77) | 69 (62–77) | 0.978 | 70 (62–77) | 69 (62–77) | 0.855 | ||
| Gender (n, %) | 1.000 | 1.000 | ||||||
| Male | 155 (66.5) | 135 (66.2) | 110 (65.9) | 111 (66.5) | ||||
| Female | 78 (33.5) | 69 (33.8) | 57 (34.1) | 56 (33.5) | ||||
| Time period (n, %) | 0.244 | 0.181 | ||||||
| 2004–2010 | 104 (44.6) | 79 (38.7) | 61 (36.5) | 74 (44.3) | ||||
| 2011–2017 | 129 (55.4) | 125 (61.3) | 106 (63.5) | 93 (55.7) | ||||
| BMI, kg/m2 (median, IQR) | 22.7 (20.9–24.5) | 22.5 (20.4–24.8) | 0.333 | 22.6 (21.0–24.5) | 22.5 (20.7–25.0) | 0.935 | ||
| Diabetes mellitus (n, %) | 0.896 | 1.000 | ||||||
| Absent | 197 (84.6) | 171 (83.8) | 139 (83.2) | 140 (83.8) | ||||
| Present | 36 (15.4) | 33 (16.2) | 28 (16.8) | 27 (16.2) | ||||
| COPD (n, %) | 1.000 | 0.620 | ||||||
| Absent | 220 (94.4) | 192 (94.1) | 160 (95.8) | 157 (94.1) | ||||
| Present | 13 (5.6) | 12 (5.9) | 7 (4.2) | 10 (6.0) | ||||
| Hemoglobin, g/dl (median, IQR) | 12.7 (11.7–13.9) | 1 2.7 (11.3–13.7) | 0.358 | 12.6 (11.7–13.9) | 12.8 (11.6–13.9) | 0.848 | ||
| Albumin, g/dl (median, IQR) | 4.1 (3.9–4.4) | 4.0 (3.7–4.3) | 0.009 | 4.1 (3.8–4.3) | 4.1 (3.8–4.3) | 0.799 | ||
| CEA, ng/ml (median, IQR) | 1.5 (0.9–2.5) | 1.6 (0.9–2.4) | 0.829 | 1.5 (0.9–2.3) | 1.6 (0.9–2.5) | 0.920 | ||
| CA19-9, U/ml (median, IQR) | 9.4 (6.0–15.3) | 9.4 (6.0–16.6) | 0.482 | 9.4 (6.5–15.0) | 9.3 (6.0–16.0) | 0.608 | ||
| Impairment of respiratory function (n, %) | 0.543 | 0.907 | ||||||
| Absent | 152 (65.2) | 139 (68.1) | 114 (68.3) | 112 (67.1) | ||||
| Present | 81 (34.8) | 65 (31.9) | 53 (31.7) | 55 (32.9) | ||||
| Clinical tumor depth (n, %) | 0.763 | 0.720 | ||||||
| cT1 | 124 (53.2) | 115 (56.4) | 94 (56.3) | 104 (62.3) | ||||
| cT2 | 53 (22.8) | 39 (19.1) | 36 (21.6) | 31 (18.6) | ||||
| cT3 | 33 (14.2) | 32 (15.7) | 23 (13.8) | 21 (12.6) | ||||
| cT4 | 23 (9.9) | 18 (8.8) | 14 (8.4) | 11 (6.6) | ||||
| Clinical lymph node metastasis (n, %) | 0.672 | 0.701 | ||||||
| cN0 | 181 (77.7) | 215 (74.5) | 133 (79.6) | 136 (81.4) | ||||
| cN1 | 40 (17.2) | 72 (18.6) | 24 (14.4) | 24 (14.4) | ||||
| cN2 | 11 (4.7) | 25 (5.4) | 9 (5.4) | 5 (3.0) | ||||
| cN3 | 1 (0.4) | 3 (1.5) | 1 (0.6) | 2 (1.2) | ||||
| Clinical TNM stage (n, %) | 0.486 | 0.868 | ||||||
| I | 161 (69.1) | 141 (69.1) | 120 (71.9) | 126 (75.5) | ||||
| IIA | 16 (6.9) | 13 (6.4) | 10 (6.0) | 9 (5.4) | ||||
| IIB | 20 (8.6) | 11 (5.4) | 13 (7.8) | 10 (6.0) | ||||
| III | 36 (15.5) | 39 (19.1) | 24 (14.4) | 22 (13.2) | ||||
| Operative procedure (n, %) | 0.658 | 1.000 | ||||||
| Distal gastrectomy | 163 (70.0) | 148 (72.6) | 123 (73.7) | 122 (73.1) | ||||
| Proximal gastrectomy | 3 (1.3) | 1 (0.5) | 0 | 1 (0.6) | ||||
| Total gastrectomy | 67 (28.8) | 55 (27.0) | 44 (26.4) | 44 (26.4) | ||||
| Operative approach (n, %) | 0.099 | 0.909 | ||||||
| Open | 107 (45.9) | 77 (37.8) | 59 (35.3) | 61 (36.5) | ||||
| Laparoscopic | 126 (54.1) | 127 (62.3) | 108 (64.7) | 106 (63.5) | ||||
| Lymph node dissection (n, %) | 0.924 | 1.000 | ||||||
| D1/D1+ | 122 (52.4) | 108 (52.9) | 96 (57.5) | 97 (58.1) | ||||
| D2 or more | 111 (47.6) | 96 (47.1) | 71 (42.5) | 70 (41.9) | ||||
Mon. Monday, Fri. Friday, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CEA carcinoembryonic antigen, CA carbohydrate antigen
Comparison of postoperative outcomes and pathologic findings between Monday and Friday groups
| Patients undergoing surgery on Mon. and Fri. (n = 437) | Propensity score-matched patients (n = 334) | |||||
|---|---|---|---|---|---|---|
| Mon. group (n = 233) | Fri. group (n = 204) | Mon. group (n = 167) | Fri. group (n = 167) | |||
| Operative time, minutes (median, IQR) | 350 (290–423) | 355 (300–430) | 0.458 | 350 (290–420) | 355 (300–430) | 0.427 |
| Operative blood loss, grams (median, IQR) | 212 (40–487) | 100 (20–433) | 0.059 | 103 (20–357) | 100 (20–390) | 0.911 |
| Blood transfusion (n, %) | 1.000 | 0.199 | ||||
| Not performed | 194 (83.3) | 170 (83.3) | 140 (83.8) | 149 (89.2) | ||
| Performed | 39 (16.7) | 34 (16.7) | 27 (16.2) | 18 (10.8) | ||
| Hospital stay after surgery, days (median, IQR) | 13 (11–18) | 12 (10–17) | 0.052 | 13 (10–18) | 12 (10–15) | 0.054 |
| Death within 30 days after surgery (n, %) | 0 (0) | 2 (1.0) | 0.217 | 0 (0) | 2 (1.2) | 0.499 |
| In-hospital death (n, %) | 0 (0) | 3 (1.5) | 0.101 | 0 (0) | 2 (1.2) | 0.499 |
| Adjuvant chemotherapy (n, %) | 0.438 | 0.651 | ||||
| Absent | 198 (85.0) | 167 (81.9) | 139 (83.2) | 143 (85.6) | ||
| Present | 35 (15.0) | 37 (18.1) | 28 (16.8) | 24 (14.4) | ||
| Tumor diameter, mm (median, IQR) | 35 (25–50) | 35 (20–60) | 0.450 | 31 (22–50) | 32 (20–51) | 0.992 |
| Retrieved number of lymph nodes (median, IQR) | 40 (27–50) | 39 (28–54) | 0.514 | 40 (29–49) | 37 (26–53) | 0.986 |
| Pathological tumor depth (n, %) | 0.207 | 0.839 | ||||
| pT1 | 130 (55.8) | 110 (53.9) | 102 (61.1) | 99 (59.3) | ||
| pT2 | 41 (17.6) | 28 (13.7) | 26 (15.6) | 25 (15.0) | ||
| pT3 | 41 (17.6) | 35 (17.2) | 25 (15.0) | 24 (14.4) | ||
| pT4 | 21 (9.0) | 31 (15.2) | 14 (8.4) | 19 (11.4) | ||
| Pathological lymph node metastasis (n, %) | 0.634 | 0.520 | ||||
| pN0 | 170 (73.0) | 144 (70.6) | 122 (73.1) | 130 (77.8) | ||
| pN1 | 26 (11.2) | 27 (13.2) | 20 (12.0) | 18 (10.8) | ||
| pN2 | 10 (4.3) | 13 (6.4) | 9 (5.4) | 4 (2.4) | ||
| pN3 | 27 (11.6) | 20 (9.8) | 16 (9.6) | 15 (9.0) | ||
| Pathological TNM stage (n, %) | 0.118 | 0.999 | ||||
| IA | 117 (50.2) | 104 (51.0) | 92 (55.1) | 93 (55.7) | ||
| IB | 41 (17.6) | 26 (12.8) | 26 (15.6) | 26 (15.6) | ||
| IIA | 24 (10.3) | 17 (8.3) | 14 (8.4) | 16 (9..6) | ||
| IIB | 17 (7.3) | 20 (9.8) | 12 (7.2) | 10 (6.0) | ||
| IIIA | 8 (3.4) | 19 (9.3) | 8 (4.8) | 8 (4.8) | ||
| IIIB | 20 (8.6) | 12 (5.9) | 12 (7.2) | 11 (6.6) | ||
| IIIC | 6 (2.6) | 6 (2.9) | 3 (1.8) | 3 (1.8) | ||
Mon. Monday, Fri. Friday, IQR interquartile range
Comparison of postoperative complications between Monday and Friday groups
| Patients undergoing surgery on Mon. and Fri. (n = 437) | Propensity score-matched patients (n = 334) | |||||
|---|---|---|---|---|---|---|
| Mon. group (n = 233) | Fri. group (n = 204) | Mon. group (n = 167) | Fri. group (n = 167) | |||
| All postoperative complications: n (%) | 47 (20.2) | 53 (26.0) | 0.171 | 35 (21.0) | 39 (23.4) | 0.693 |
| Anastomotic leakage | 5 (2.2) | 6 (2.9) | 0.762 | 5 (3.0) | 5 (3.0) | 1.000 |
| Pancreatic fistula | 8 (3.4) | 5 (2.5) | 0.587 | 6 (3.6) | 4 (2.4) | 0.750 |
| Intra-abdominal abscess | 6 (2.6) | 6 (2.9) | 1.000 | 5 (3.0) | 4 (2.4) | 1.000 |
| Anastomotic stenosis | 3 (1.3) | 5 (2.5) | 0.482 | 3 (1.8) | 4 (2.4) | 1.000 |
| Pneumonia | 5 (2.2) | 15 (7.4) | 0.011 | 3 (1.8) | 9 (5.4) | 0.139 |
| Paralytic ileus | 5 (2.2) | 2 (1.0) | 0.457 | 5 (3.0) | 1 (0.6) | 0.215 |
| Stasis syndrome | 6 (2.6) | 1 (0.5) | 0.128 | 3 (1.8) | 0 | 0.248 |
| Surgical site infection | 2 (0.9) | 3 (1.5) | 0.668 | 1 (0.6) | 3 (1.8) | 0.623 |
| Urinary-tract infection | 2 (0.9) | 2 (1.0) | 1.000 | 2 (1.2) | 2 (1.2) | 1.000 |
| Bacteremia | 2 (0.9) | 3 (1.5) | 0.668 | 1 (0.6) | 3 (1.8) | 0.623 |
| Delirium | 6 (2.6) | 9 (4.4) | 0.307 | 5 (3.0) | 4 (2.4) | 1.000 |
| Pleural effusion | 2 (0.9) | 1 (0.5) | 1.000 | 2 (1.2) | 1 (0.6) | 1.000 |
| Heart failure | 4 (1.7) | 3 (1.5) | 1.000 | 2 (1.2) | 2 (1.2) | 1.000 |
| Bleeding | 2 (0.9) | 0 | 0.501 | 2 (1.2) | 0 | 0.499 |
| Enteritis | 0 | 0 | 0 | 0 | ||
| Other | 3 (1.3) | 3 (1.5) | 1.000 | 2 (1.2) | 2 (1.2) | 1.000 |
Mon. Monday, Fri. Friday
Fig. 4Kaplan–Meier curves comparing Monday and Friday for overall survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients
Fig. 5Kaplan–Meier curves comparing Monday and Friday for recurrence-free survival after propensity score matching. a All patients, b pathologic stage I patients, c stage II patients, and d stage III patients